PriceTargets.com logo

DICE Therapeutics - DICE Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $62.60
  • Forecasted Upside: 89.93%
  • Number of Analysts: 11
  • Breakdown:
  • 0 Sell Ratings
  • 1 Hold Ratings
  • 10 Buy Ratings
  • 0 Strong Buy Ratings
$32.96 As of 06/9/2023 01:00 AM ET
▲ +0.38 (1.17%)

This chart shows the closing price for DICE by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New DICE Therapeutics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for DICE and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for DICE

Analyst Price Target is $62.60
▲ +89.93% Upside Potential
This price target is based on 11 analysts offering 12 month price targets for DICE Therapeutics in the last 3 months. The average price target is $62.60, with a high forecast of $77.00 and a low forecast of $38.00. The average price target represents a 89.93% upside from the last price of $32.96.

This chart shows the closing price for DICE for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 11 investment analysts is to buy stock in DICE Therapeutics.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/16/2021
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/16/2022
  • 0 strong buy ratings
  • 3 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
6/14/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
9/12/2022
  • 0 strong buy ratings
  • 5 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
12/11/2022
  • 0 strong buy ratings
  • 8 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
3/11/2023
  • 0 strong buy ratings
  • 9 buy ratings
  • 0 hold ratings
  • 0 sell ratings
Ratings as of
5/10/2023
  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
6/9/2023

Latest Recommendations

  • 0 strong buy ratings
  • 10 buy ratings
  • 1 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
5/24/2023Wells Fargo & CompanyInitiated CoverageEqual Weight$38.00Low
5/22/2023Canaccord Genuity GroupInitiated CoverageBuy$71.00Low
3/31/2023Needham & Company LLCInitiated CoverageBuy$56.00Low
3/16/2023HC WainwrightReiterated RatingBuy$60.00Low
3/8/2023HC WainwrightReiterated RatingBuy$60.00Low
3/1/2023TD CowenInitiated CoverageOutperformLow
3/1/2023CowenInitiated CoverageOutperformLow
3/1/2023CowenInitiated CoverageOutperformLow
11/15/2022GuggenheimInitiated CoverageBuy$65.00Low
10/11/2022Bank of AmericaBoost Target$34.00 ➝ $62.00Low
10/11/2022SVB LeerinkBoost TargetOutperform ➝ Outperform$46.00 ➝ $77.00Low
10/11/2022HC WainwrightBoost TargetBuy$40.00 ➝ $60.00Low
10/11/2022Cantor FitzgeraldBoost Target$36.00 ➝ $68.00Low
10/11/2022Evercore ISIBoost Target$45.00 ➝ $75.00Low
10/11/2022Stifel NicolausBoost Target$37.00 ➝ $54.00Low
9/14/2022Cantor FitzgeraldInitiated CoverageOverweight$36.00Low
9/6/2022Stifel NicolausInitiated CoverageBuy$37.00Low
7/18/2022HC WainwrightInitiated CoverageBuy$40.00Low
10/11/2021SVB LeerinkInitiated CoverageOutperform$46.00High
10/11/2021Bank of AmericaInitiated CoverageBuy$41.00High
10/11/2021Evercore ISIInitiated CoverageOutperform$60.00High
(Data available from 6/9/2018 forward)

News Sentiment Rating

0.50 (Buy)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 11 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
11/11/2022
  • 1 very positive mentions
  • 5 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
12/11/2022
  • 1 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
1/10/2023
  • 1 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
2/9/2023
  • 3 very positive mentions
  • 3 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
3/11/2023
  • 3 very positive mentions
  • 18 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
4/10/2023
  • 7 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
5/10/2023
  • 10 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
Mentions as of
6/9/2023

Current Sentiment

  • 10 very positive mentions
  • 22 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Negative

Positive

Very Positive

DICE Therapeutics logo
DICE Therapeutics, Inc., a biopharmaceutical company, builds various oral therapeutic candidates to treat chronic diseases in immunology and other therapeutic areas. Its platform DELSCAPE is designed to discover selective oral small molecules to modulate protein-protein interactions as effectively as systemic biologics. The company's lead therapeutic candidate is DC-806, an oral antagonist of the pro-inflammatory signaling molecule, interleukin-17 (IL-17) that is a validated drug target implicated in a various immunology indications. It also develops DC-853, an oral IL-17 antagonist. In addition, the company is developing oral therapeutic candidates targeting alpha 4 beta 7 integrin for the treatment of inflammatory bowel diseases, as well as targeting alpha V beta 1/ alpha V beta 6 integrin for the treatment of idiopathic pulmonary fibrosis. Further, it focuses on programmed death-ligand 1 program, an immuno-oncology targeting antibody therapeutics. The company was founded in 2013 and is headquartered in South San Francisco, California.
Read More

Today's Range

Now: $32.96
Low: $32.00
High: $33.08

50 Day Range

MA: $32.24
Low: $25.86
High: $38.24

52 Week Range

Now: $32.96
Low: $12.64
High: $45.99

Volume

338,294 shs

Average Volume

456,772 shs

Market Capitalization

$1.57 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

0.69

Frequently Asked Questions

What sell-side analysts currently cover shares of DICE Therapeutics?

The following equities research analysts have issued reports on DICE Therapeutics in the last twelve months: Bank of America Co., Canaccord Genuity Group Inc., Cantor Fitzgerald, Cowen Inc, Cowen Inc., Evercore ISI, Guggenheim, HC Wainwright, Needham & Company LLC, Stifel Nicolaus, SVB Leerink LLC, TD Cowen, and Wells Fargo & Company.
View the latest analyst ratings for DICE.

What is the current price target for DICE Therapeutics?

10 Wall Street analysts have set twelve-month price targets for DICE Therapeutics in the last year. Their average twelve-month price target is $62.60, suggesting a possible upside of 89.9%. SVB Leerink LLC has the highest price target set, predicting DICE will reach $77.00 in the next twelve months. Wells Fargo & Company has the lowest price target set, forecasting a price of $38.00 for DICE Therapeutics in the next year.
View the latest price targets for DICE.

What is the current consensus analyst rating for DICE Therapeutics?

DICE Therapeutics currently has 1 hold rating and 10 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe DICE will outperform the market and that investors should add to their positions of DICE Therapeutics.
View the latest ratings for DICE.

What other companies compete with DICE Therapeutics?

Other companies that are similar to DICE Therapeutics include Dynavax Technologies, Biohaven, Taro Pharmaceutical Industries, Zentalis Pharmaceuticals and Keros Therapeutics. Learn More about companies similar to DICE Therapeutics.

How do I contact DICE Therapeutics' investor relations team?

DICE Therapeutics' physical mailing address is 279 E. GRAND AVENUE SUITE 300 LOBBY B, SOUTH SAN FRANCISCO CA, 94080. The company's listed phone number is 650-566-1420 and its investor relations email address is inve[email protected]. The official website for DICE Therapeutics is www.dicemolecules.com. Learn More about contacing DICE Therapeutics investor relations.